Trial Profile

First-in-Human Phase I Clinical Trial for TSP-101

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TSP 101 (Primary)
Indications Cachexia
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Tensegrity Pharma

Most Recent Events

09 Feb 2026 New trial record
15 Dec 2025 According to Tensegrity Pharma media release, company has announced that the first subject has been successfully dosed (First-Subject-In) in its Phase I company-sponsored clinical trial of TSP-101 in Japan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com